#USA #Chicago #Zentiva #pharmaceuticals #GTCR

GTCR Finalizes Acquisition of Zentiva

On April 9, 2026, GTCR, a prominent private equity firm, announced the successful conclusion of its acquisition of Zentiva, a leading generics pharmaceutical company in Europe. This strategic move follows a detailed agreement with Advent, another key player in the global private equity landscape.

Zentiva specializes in the development, manufacturing, and distribution of a wide array of pharmaceutical products, including generic, branded specialty, and over-the-counter drugs. The company’s reach extends to over 40 countries, servicing more than 100 million patients worldwide. With established research and development capabilities, Zentiva is committed to clinical excellence and high product quality.

In embarking on this new chapter, GTCR plans to work closely with Zentiva’s executive team, including CEO Steffen Saltofte and Executive Chairperson Kieran Murphy. Both Saltofte and Murphy bring rich industry experience from their previous roles at well-known healthcare firms such as Acino and GE HealthCare.

"We are enthusiastic about the potential that lies ahead for Zentiva as we enter this new phase of growth," remarked Saltofte, emphasizing the firm’s dedication to expanding access to high-quality and affordable medicines across Europe. GTCR's extensive experience in the healthcare sector positions them uniquely to support Zentiva's initiatives aimed at enhancing patient access to essential medications and strengthening healthcare systems.

Sean Cunningham, Managing Director and Head of Healthcare at GTCR, also weighed in, underscoring the increasing emphasis policymakers are placing on expanding access to vital medicines. Cunningham noted that Zentiva’s role as a reliable provider of high-quality and cost-effective therapies is crucial in meeting these demands.

Zentiva is well prepared to leverage its competitive advantages, including an efficient geographic footprint and cost-effective manufacturing practices, to facilitate long-term growth and greater market impact.

Tom Allen, Managing Director at Advent, expressed pride in what Zentiva has achieved during their partnership, recognizing it as a robust European generics platform with a clear mission to enhance access to affordable medicines. He commended the talented team at Zentiva for their dedication throughout the company's transformative journey.

The acquisition has been facilitated with the guidance of several financial advisory firms. GTCR received support from Barclays, BNP Paribas, Morgan Stanley, and legal counsel from Kirkland & Ellis. Advent was similarly advised by Goldman Sachs, PJT Partners, and Freshfields.

GTCR, founded in 1980, has a distinguished investment history with significant capital injection into healthcare ventures, amounting to over $30 billion across approximately 300 companies. The firm operates with an investment philosophy known as The Leaders Strategy™, focusing on partnering with management leaders to drive market-leading company growth through both organic means and strategic acquisitions. With bases in Chicago, New York, and West Palm Beach, GTCR aims to influence the future of the healthcare industry positively.

In summary, this acquisition represents not only a new era for Zentiva but also a reaffirmation of GTCR's commitment to healthcare investments aimed at creating lasting impacts by enhancing patient access to vital medicines across Europe and beyond.

Visit Zentiva’s website for more details on their diverse portfolio and commitment to health and wellness.